These initial studies found that plasma IL-2 was significantly increased in stable COPD subjects compared to those with rapidly progressive disease while plasma eotaxin-1 levels were significantly lower in stable COPD subjects compared to controls. This evidence concerns the gene CCL11 and glycogen storage disease VI.